Jonathan Brayman is a Managing Director in Blackstone Credit and Insurance (BXCI) based in New York. Mr. Brayman is focused on private credit, structured equity, and royalty monetizations in Healthcare & Life Sciences. Mr. Brayman has been involved in Blackstone’s investments in Alnylam Pharmaceuticals, Amicus Therapeutics, PTC Therapeutics, Harmony Biosciences, Simtra (fka Baxter Biopharma Solutions), Ritedose, Inovalon, Personify Health (fka Virgin Pulse/HealthComp), Unified Women’s Healthcare, and The GI Alliance, among others. Mr. Brayman opened BXCI’s Life Sciences office in Cambridge, MA.

Before joining Blackstone in 2015, Mr. Brayman worked as an Investment Banking Analyst at Houlihan Lokey, where he advised Healthcare companies on mergers and acquisitions.

Mr. Brayman graduated summa cum laude with a BS in Commerce and Business Administration and a double major in Finance and Economics from the University of Alabama.